Clinical Prognostic Values of Vascular Endothelial Growth Factor, Microvessel Density,and p53 Expression in Esophageal Carcinomas

Myung‐Ju Ahn(Sungkyunkwan University), Chan Kum Park(Hanyang University), Chul Burm Lee(Hanyang University), Hong Kyu Paik(Hanyang University), Se Jin Jang(University of Ulsan), Jung Hye Choi(Hanyang University Guri Hospital), Yong Wook Park(Hanyang University), Ho Suk Oh(Hanyang University)

Journal of Korean Medical Science

January 1, 2002

10.3346/jkms.2002.17.2.201

Cited by 34

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

|New England Journal of Medicine|2016|3.3k

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

|The Lancet|2018|1.7k

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

|The Lancet Oncology|2019|537